INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,947,000 | -49.4% | 52,213 | -65.2% | 0.06% | -70.2% |
| Q3 2020 | $3,849,000 | +372.3% | 150,000 | +37.5% | 0.20% | +42.4% |
| Q3 2019 | $815,000 | -79.1% | 109,130 | -63.6% | 0.14% | -76.5% |
| Q2 2019 | $3,894,000 | +219.7% | 300,000 | +200.0% | 0.59% | +241.6% |
| Q1 2019 | $1,218,000 | +285.4% | 100,000 | +261.0% | 0.17% | +174.6% |
| Q4 2018 | $316,000 | -92.5% | 27,700 | -85.7% | 0.06% | -92.8% |
| Q3 2018 | $4,191,000 | +427.2% | 193,100 | +329.1% | 0.88% | +177.0% |
| Q2 2018 | $795,000 | – | 45,000 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |